Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Attention Deficit/Hyperactivity Disorder
Interventions: centanafadine capsule, placebo capsule; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 574 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV-1 Infection
Interventions: DOR/ISL, BIC/FTC/TAF, Placebo to DOR/ISL, Placebo to BIC/FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 38
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 29 more

Conditions: Metabolism and Nutrition Disorder, Overweight or Obesity
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 39
States / cities: Anniston, Alabama • Anaheim, California • Lomita, California + 32 more

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Costa Mesa, California • Honolulu, Hawaii + 4 more

Conditions: Migraine
Interventions: ASY202, Placebo; Combination Product
Lead sponsor: Aspeya, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Lemon Grove, California • Walnut Creek, California + 16 more

Conditions: HIV Infections
Interventions: INCB009471, Placebo comparator; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more

Conditions: Nausea and Vomitting
Interventions: TAK-951, TAK-951 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Diabetic Kidney Disease
Interventions: INV-202, Placebo; Drug
Lead sponsor: Inversago Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Garden Grove, California • Pomona, California • Salinas, California + 19 more

Conditions: Autoimmune Encephalitis, Encephalitis
Interventions: Inebilizumab, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 12 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: any statin, niacin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 1 Diabetes Mellitus
Interventions: TAK-329, Insulin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Cataract
Interventions: MELT-300, Midazolam alone, Ketamine alone, Placebo; Drug
Lead sponsor: Melt Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Rancho Cordova, California • Jacksonville, Florida • West Fargo, North Dakota

Conditions: Healthy Volunteers
Interventions: AZD8108, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 258 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteopenia, Osteoporosis
Interventions: BPS804 20mg/Kg, Placebo to 20mg/Kg BPS804; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 45 Years to 85 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: Anaheim, California • Miami, Florida • Berlin, New Jersey + 1 more

Conditions: Healthy
Interventions: HNC042 single dose, Placebo single dose, HNC042 multiple ascending doses, Placebo multiple ascending doses; Drug
Lead sponsor: Guangzhou Henovcom Bioscience Co. Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Kidney Disease Associated Moderate to Severe Pruritus
Interventions: Nemolizumab, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 47
States / cities: Bakersfield, California • Glendale, California • La Palma, California + 40 more

Conditions: Complicated Intra-abdominal Infection
Interventions: CXA-101/ tazobactam and metronidazole, meropenem plus saline placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 90 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Orange, California • Torrance, California • Aurora, Colorado + 8 more

Conditions: Alcohol Use Disorder
Interventions: Ibudilast, Placebo; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Herpes Genitalis
Interventions: Valaciclovir, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 58
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: Bilateral Nasal Polyposis
Interventions: OPN-375; Drug
Lead sponsor: Optinose US Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 22
States / cities: Gilbert, Arizona • Bakersfield, California • Fresno, California + 18 more

Conditions: Cardiovascular Disease
Interventions: Cagrilintide, Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 55 Years and older
Enrollment: 7,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 119
States / cities: Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 103 more

Conditions: Diabetes Mellitus
Interventions: Alogliptin and glyburide, Glyburide; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 54
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 51 more

Conditions: Schizophrenia
Interventions: Placebo, Emraclidine 10 mg, Emraclidine 30 mg; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 21
States / cities: Little Rock, Arkansas • Anaheim, California • Garden Grove, California + 18 more

Conditions: Depression
Interventions: Naltrexone; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients

A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

TAK-329 Glucose Clamp Study

A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)

AZD8108 SAD/MAD in Healthy Volunteers

Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density

A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus

Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections

Ibudilast and Withdrawal-Related Dysphoria

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)